Company overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing MNOV with another company.
| Daily close (USD) | $1.54 |
| Market capitalization (USD) | $75,800,718.84 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.03 |
No matching rows. Clear the filter to see all records.
Read MNOV's valuation metrics
Company size
Medicinova, Inc.'s recorded market capitalization is $75,800,718.84. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
MNOV's recorded price-to-book ratio is 2.03. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Medicinova, Inc. with Aurora
Use the snapshot above to ask a specific question about MNOV. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MNOV's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.